We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+11.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.92B
AUM Growth
-$2.46M
Cap. Flow
-$105M
Cap. Flow %
-2.67%
Top 10 Hldgs %
77.48%
Holding
132
New
21
Increased
29
Reduced
29
Closed
20
Avg Time Held Equity + Options
7 quarters
Top 10 Avg Time Held Equity + Options
4.2 quarters
Top 20 Avg Time Held Equity + Options
7.5 quarters
Avg Time Held Equity only
7.1 quarters
Top 10 Avg Time Held Equity only
7.2 quarters
Top 20 Avg Time Held Equity only
9.1 quarters

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$103M
2
CGEM icon
Cullinan Oncology
CGEM
+$22.5M
3
RNAM
Avidity Biosciences
RNAM
+$18.8M
4
VERA icon
Vera Therapeutics
VERA
+$16.3M
5
JBIO icon
Jade Biosciences
JBIO
+$15.3M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$232M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$29.5M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.8M
4
ALPN icon
Alpine Immune Sciences Inc
ALPN
+$16.1M
5
ONC icon
BeOne Medicines Ltd
ONC
+$15.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 56.02%
2 Healthcare 41.9%
3 Technology 0.98%
4 Miscellaneous 0.71%
5 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CNTA
26
DELISTED
Centessa Pharmaceuticals
CNTA
$19.1M 0.49%
2,112,500
+700,000
+50% +$6.64M
2023 Q4
2 quarters
CGEM icon
27
Cullinan Oncology
CGEM
$999M
$18.5M 0.47%
+1,057,949
New +$22.5M
2024 Q2
0 quarters
NAMS icon
28
NewAmsterdam Pharma
NAMS
$2.58B
$15.4M 0.39%
800,000
– –
2024 Q1
1 quarter
XENE icon
29
Xenon Pharmaceuticals
XENE
$3.53B
$14.9M 0.38%
381,554
+128,167
+51% +$5.12M
2024 Q1
1 quarter
EWTX icon
30
Edgewise Therapeutics
EWTX
$4.24B
$14.6M 0.37%
811,718
– –
2024 Q1
1 quarter
SLDB icon
31
Solid Biosciences
SLDB
$737M
$14.2M 0.36%
2,500,000
– –
2021 Q1
13 quarters
KRRO icon
32
Korro Bio
KRRO
$150M
$14M 0.36%
413,072
-6,154
-1% -$340K
2023 Q4
2 quarters
ASND icon
33
Ascendis Pharma A/S
ASND
$15.1B
$13.8M 0.35%
+101,100
New +$13.8M
2024 Q2
0 quarters
AGEN icon
34
Agenus
AGEN
$346M
$13M 0.33%
775,000
-6,562
-0.8% -$79.3K
2013 Q2
44 quarters
SYRS icon
35
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$12.9M 0.33%
2,505,013
– –
2020 Q1
17 quarters
GOSS icon
36
Gossamer Bio
GOSS
$56.9M
$12M 0.31%
166,362
– –
2019 Q1
21 quarters
DNLI icon
37
Denali Therapeutics
DNLI
$3.11B
$11.7M 0.3%
502,899
– –
2017 Q4
26 quarters
RARE icon
38
Ultragenyx Pharmaceutical
RARE
$1.53B
$11.3M 0.29%
275,000
+97,068
+55% +$4.14M
2024 Q1
1 quarter
BHVN icon
39
Biohaven
BHVN
$1.82B
$10.6M 0.27%
+306,703
New +$12.1M
2024 Q2
0 quarters
TSHA icon
40
Taysha Gene Therapies
TSHA
$1.46B
$9.75M 0.25%
4,354,214
+666,666
+18% +$1.94M
2020 Q3
15 quarters
LXEO icon
41
Lexeo Therapeutics
LXEO
$265M
$9.68M 0.25%
603,435
-198,281
-25% -$2.88M
2023 Q4
2 quarters
SLRN icon
42
DELISTED
ACELYRIN
SLRN
$8.91M 0.23%
2,020,888
-384,255
-16% -$1.8M
2023 Q2
4 quarters
JANX icon
43
Janux Therapeutics
JANX
$1.12B
$8.5M 0.22%
203,000
+153,000
+306% +$7.18M
2024 Q1
1 quarter
RNAC icon
44
Cartesian Therapeutics
RNAC
$213M
$8.23M 0.21%
304,554
-1
-0% -$24
2018 Q1
25 quarters
RAPP icon
45
Rapport Therapeutics
RAPP
$1.47B
$8.14M 0.21%
+350,000
New +$8.1M
2024 Q2
0 quarters
IOVA icon
46
Iovance Biotherapeutics
IOVA
$6.62B
$8.11M 0.21%
+1,011,500
New +$10.8M
2024 Q2
0 quarters
GBIO icon
47
DELISTED
Generation Bio
GBIO
$7.98M 0.2%
283,059
– –
2020 Q2
16 quarters
SEER icon
48
Seer Inc
SEER
$121M
$7.98M 0.2%
4,750,000
– –
2020 Q4
14 quarters
VIGL icon
49
DELISTED
Vigil Neuroscience
VIGL
$7.31M 0.19%
1,828,691
+17,500
+1% +$59.9K
2022 Q1
9 quarters
DFTX icon
50
Definium Therapeutics
DFTX
$4.96B
$7.27M 0.19%
+1,007,875
New +$8.81M
2024 Q2
0 quarters
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2024 Portfolio in Review

As of Q2 2024, Artal Group held 132 positions worth $3.92B, down 0.06% from $3.93B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Artal Group's Q2 2024 filing shows 21 new, 29 increased, 29 reduced and 20 closed positions. Its largest new stake was Cullinan Oncology: 1,057,949 shares worth $18.5M. The largest sale was CAVA Group, an estimated $232M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 56% of assets, up from 48% a quarter earlier, followed by Healthcare and Technology.

  • Artal Group's largest Q2 2024 buy was Cullinan Oncology: 1,057,949 shares worth $18.5M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2024, an estimated $103M increase.
  • Artal Group's biggest Q2 2024 reduction was CAVA Group, cutting an estimated $232M.
  • Artal Group fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $29.5M.
  • Artal Group's ten largest holdings make up 77% of its $3.92B portfolio in Q2 2024.
  • Artal Group opened 21 new positions and closed 20 in Q2 2024.
  • Artal Group's portfolio value fell 0.06% quarter-over-quarter to $3.92B.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.